XML 25 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Stock-based Compensation and Equity Transactions
9 Months Ended
Jul. 31, 2020
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]
Note
7
Stock-based compensation and equity transactions
 
On
December 3, 2018,
two
employees were each granted
25,000
incentive stock options. These options vested
5,000
each on the date of grant, and the balance vests as to
5,000
shares each per year thereafter on each of the next
four
anniversaries of
December 3, 2018,
and expire
ten
years from the date of grant. Also on
December 3, 2018,
one
employee was granted
10,000
incentive stock options. These options vested
2,000
shares on the date of grant, and the balance vests as to
2,000
shares per year thereafter on each of the next
four
anniversaries of
December 3, 2018,
and expire
ten
years from the date of grant.
 
On
March 8, 2019,
one
employee was granted
25,000
incentive stock options. These options vested
5,000
on the date of grant, and the balance vests as to
5,000
shares per year thereafter on each of the next
four
anniversaries of
March 8, 2019,
and expire
ten
years from the date of grant.
 
On
December 6, 2019,
one
employee was granted
50,000
incentive stock options. These options vested
10,000
on the date of grant, and the balance vests as to
10,000
shares per year thereafter on each of the next
four
anniversaries of
December 6, 2019,
and expire
ten
years from the date of grant.
 
On
January 9, 2020,
we granted the following equity awards to our managers and officers:
 
 
Stock grants for a total of
12,075
common shares to
three
employees. We accounted for these shares as stock-based compensation totaling
$77,000;
 
A total of
3,241
incentive stock options to
two
employees, all of which vested immediately on the date of grant; and
 
A total of
38,500
shares of restricted stock and
77,000
incentive stock options to
five
employees. The shares of restricted stock and incentive stock options vest over
four
years as follows: (i)
one
-quarter of the restricted shares and options shall vest on
January 9, 2021;
and (ii) the remaining restricted shares and options shall vest in
twelve
equal quarterly installments over the next
three
years, commencing with the
first
quarter following
January 9, 2021.
All incentive stock options expire
ten
years from the date of grant.
 
On
June 30, 2020,
one
employee was granted
10,000
incentive stock options. These options vested
2,500
on the date of grant, and the balance vests as to
2,500
shares per year thereafter on each of the next
three
anniversaries of
June 30, 2020,
and expire
ten
years from the date of grant.
 
No
other shares or options were granted to company employees during the
three
and
nine
months ended
July 31, 2020
and
2019.
 
The weighted average fair value of employee stock options that were granted during the
nine
months ended
July 31, 2020
and
2019
was estimated to be
$3.06
and
$3.98,
respectively, per share, using the Black-Scholes option pricing model with the following assumptions:
 
   
Nine Months Ended July 31,
 
   
2020
   
2019
 
Risk-free interest rate
   
1.58
%    
2.86
%
Dividend yield
   
0.63
%    
0.98
%
Expected life of the option (in years)
   
7.01
     
5.90
 
Volatility factor
   
52.68
%    
55.42
%
 
Expected volatilities are based on historical volatility of our stock price and other factors. We used the historical method to calculate the expected life of the
2020
and
2019
option grants. The expected life represents the period of time that options granted are expected to be outstanding. The risk-free rate is based on the U.S. Treasury rate with a maturity date corresponding to the options' expected life. The dividend yield is based upon the historical dividend yield.
 
Company stock option plans
 
Descriptions of our stock option plans are included in Note
10
of our Annual Report on Form
10
-K for the year ended
October 31, 2019.
A summary of the status of the options granted under our stock option plans as of
July 31, 2020
and the changes in options outstanding during the
nine
months then ended is presented in the table that follows:
 
   
 
 
 
 
Weighted
 
   
 
 
 
 
Average
 
   
Shares
   
Exercise Price
 
Outstanding at November 1, 2019
   
890,147
    $
3.62
 
Options granted
   
140,241
    $
6.40
 
Options exercised
   
(241,209
)   $
1.85
 
Options outstanding at July 31, 2020
   
789,179
    $
4.66
 
Options exercisable at July 31, 2020
   
459,513
    $
4.48
 
Options vested and expected to vest at July 31, 2020
   
788,143
    $
4.67
 
 
Weighted average remaining contractual life of options outstanding as of
July 31, 2020:
4.98
years
 
Weighted average remaining contractual life of options exercisable as of
July 31, 2020:
2.84
years
 
Weighted average remaining contractual life of options vested and expected to vest as of
July 31, 2020:
4.97
years
 
Aggregate intrinsic value of options outstanding at
July 31, 2020:
$719,000
 
Aggregate intrinsic value of options exercisable at
July 31, 2020:
$433,000
 
Aggregate intrinsic value of options vested and expected to vest at
July 31, 2020:
$714,000
 
As of
July 31, 2020,
$619,000
and
$255,000
of expenses with respect to nonvested stock options and restricted shares, respectively, has yet to be recognized but is expected to be recognized over a weighted average period of
4.31
and
1.27
years, respectively.
 
Non-employee directors receive a compensation package of
$50,000
annually, which is paid
one
-half in cash and
one
-half through the grant of non-qualified awards. For fiscal
2020,
compensation payable to non-employee directors will be prorated from
November 1, 2019
through
August 31, 2020.
On
November 4, 2019,
we granted each of our
five
non-employee directors
3,270
shares of restricted stock. The number of restricted shares granted to each director was determined by prorating
$25,000
for the
10
months ending
August 31, 2020
and dividing by the
20
-day average RFIL stock price (
$6.36
). These restricted shares vest ratably through
August 31, 2020.
 
Non-employee directors who are also a chairperson of a committee of the Board receive additional compensation of
$15,000
annually, which is payable in cash. On
June 5, 2020,
the Board of Directors revised the committee chair compensation so that all future compensation from
July 1, 2020
through the next annual meeting of the stockholders will be payable in shares of common stock rather than cash. Shares issued as compensation will be valued at the closing RFIL stock price on the last day of each quarter. Accordingly, on
July 31, 2020,
each of the
four
committee chairpersons was awarded
279
shares at
$4.47
per share.  Beginning
August 1, 2020,
the full
$15,000
additional compensation will be payable in shares of common stock valued at the closing RFIL stock price on the last day of the quarter. We account for these shares as stock-based compensation.
 
Stock option expense
 
During the
three
months ended
July 31, 2020
and
2019,
stock-based compensation expense totaled
$166,000
and
$68,000,
respectively, and was classified in selling and general expense. During the
nine
months ended
July 31, 2020
and
2019,
stock-based compensation expense totaled
$449,000
and
$260,000,
respectively, and was classified in selling and general expenses.